Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 215-149-9
CAS number: 1306-25-8
The objective of this study was to determine the toxicology,
accumulation and toxicokinetics of cadmium telluride in the rat and for
a direct comparative bioavailability assessment with the chosen
reference substance, cadmium chloride. It was proposed that this study
should follow, as closely as possible, the experimental design used in
the study by Loeser and Lorke, 1977 ((https://doi.org/10.1016/0300
, a study that investigated the sub-chronic toxicity and accumulation of
cadmium in the liver and kidney in the rat dosed with cadmium chloride
in the diet at 30 ppm.
In Weeks 1, 4 and 8 three animals/sex/test item group were sacrificed
for bioanalytical purposes. Prior to sacrifice, blood, urine and faeces
were collected to determine the Cadmium and Tellurium content. In Week
13, the remaining animals were sacrificed for bioanalytical and
toxicological assessment purposes. Control group animals were only
sacrificed in Weeks 1 and 13.
Samples of diets were collected for analysis. Chemical analyses of
dietary preparations were conducted on Weeks 1 and 6 to assess
concentration and homogeneity.
The following parameters and endpoints were evaluated in this study:
clinical signs, body weights, food consumption, clinical pathology
parameters (haematology, coagulation and clinical chemistry),
toxicokinetic parameters, gross necropsy findings and organ weights.
Test diets prepared were considered homogeneous at the concentrations
tested in Week 1 and analysis of the accuracy revealed acceptable levels
in Weeks 1 and 6. The diets of Groups 2 and 3 prepared for use in Week 1
were not homogeneous. As the homogeneity results were slightly outside
the acceptable range (≤ 20%) and based on the evaluation made prior to
start of the study (documented in appendix 3 of report), these results
had no impact on the outcome of the study.
Overall, dietary analyses confirmed that diets were prepared accurately
and were acceptable homogenously for the purposes of this study.
At 750 ppm Cadmium telluride, no test item-related findings were
At 1500 ppm Cadmium telluride, no test item-related clinical signs were
observed. A trend towards a non-adverse slightly lower body weight and
body weight gain was seen in males. Results of the haematology
examinations showed lower mean levels of red blood cells and
reticulocytes, red blood cell distribution width, haemoglobin and
haematocrit were observed in males at 1500 ppm Cadmium telluride. In
females at 1500 ppm Cadmium telluride, only red blood cell distribution
width was decreased. Given the slight degree of these variations and as
they were mostly within historical control range, these were considered
to be not adverse.
Clinical chemistry findings were a decrease in total bilirubin and
triglyceride levels in females at 1500 ppm Cadmium telluride. As these
changes were relatively slight and remained within the historical
control range, these findings were considered to be not adverse.
At 30 ppm Cadmium chloride, alopecia was observed in females, which is
likely to be test item-related. No changes in body weights and
haematology parameters were observed. Clinical chemistry findings
included a decrease in total bilirubin and triglyceride levels in
females at 30 ppm Cadmium chloride, which remained within the historical
control range and was therefore considered to be not adverse. One male
showed increases in alanine aminotransferase (ALAT) and aspartate
aminotransferase (ASAT) activities and urea, creatinine and glucose
levels and decreases in total protein, albumin, (HDL and LDL)
cholesterol and calcium levels. Furthermore, thyroid-stimulating hormone
(TSH) and triiodothyronine (T3) levels were also decreased in this
animal. In one male and one female also an increase in TSH levels were
observed. At the severity affected, but in absence of histopathology,
these findings were considered to be not adverse. At necropsy, a foci in
the stomach was seen in one male in Week 4 and one male at the end of
treatment. In absence of any related changes in food consumption and
body weight, this isolated finding was considered to be not adverse.
No test item-related changes were noted in any of the remaining
parameters investigated in this study (i.e. food consumption,
coagulation and organ weights).
In conclusion, administration of Cadmium telluride by dietary
administration for at least 90 days was well tolerated in rats at levels
up to 1500 ppm (corresponding to a mean test article intake of 103 and
121 mg/kg body weight in males and females, respectively). Only slight
non-adverse changes in haematology and clinical chemistry parameters
were seen. The findings observed in animals treated with 30 ppm Cadmium
chloride were limited to alopecia and changes in several clinical
The results of this study have demonstrated a significant difference in
bioavailability potential between a relatively soluble cadmium compound,
Cadmium chloride (the reference substance) and a relatively insoluble
cadmium compound, cadmium telluride (test substance).
Cadmium telluride exhibited no evidence of bioavailability by dietary
administration for 90 days at high dose levels of 750 and 1500 ppm. No
detectable and/or reliable levels of either cadmium or tellurium were
detected in the target organs (liver and kidney), plasma and urine.
In contrast, in the Cadmium chloride group, at a much lower dose level
of (30 ppm), the Cadmium levels increased in the kidney and liver in
line with the Loeser and Lorke study (1977).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Ce site web utilise des cookies afin de vous garantir la meilleure expérience possible sur nos sites web.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again